Oritavancin--an investigational glycopeptide antibiotic (Q36426011)

14 August 2017

1 reference

title

Oritavancin--an investigational glycopeptide antibiotic (English)

1 reference

14 August 2017

Kristina E Ward

1

1 reference

14 August 2017

Tracey L Mersfelder

series ordinal

2

1 reference

14 August 2017

Kerry L LaPlante

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Investigational Drugs

14 August 2017

1 reference

14 August 2017

15

1 reference

14 August 2017

4

1 reference

14 August 2017

417-429

1 reference

Vancomycin-resistant staphylococci and enterococci: epidemiology and control

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Trends in antimicrobial drug development: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Mechanism of action of oritavancin and related glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Structural modifications of glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Study on the in-vitro activity of LY333328 against gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Vancomycin-tolerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

The post-antibiotic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Consequences of cellular cholesterol accumulation: basic concepts and physiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Approaches to vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro activity of LY146032 against staphylococci, streptococci, and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro bactericidal activity of daptomycin against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.417

10.1517/13543784.15.4.417

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference